The goal of this proposal is to assess the bone repair potential of human bone marrow cells transduced with a lentiviral vector containing the cDNA for BMP-2. There are a number of difficult bone repair scenarios for which there is no consistently satisfactory solution including: fracture nonunion, acute fractures with extensive bone loss, revision total joint arthroplasty and pseudarthrosis of the spine. Traditionally, autologous bone graft has been the gold standard but there is a limited supply of this bone and there are concerns regarding the morbidity associated with graft harvest. Recombinant bone morphogenetic proteins (BMP) are FDA approved for use in spinal fusion and treatment of fresh tibial fractures. However, BMPs have had mixed success in humans and are associated with side effects including soft tissue edema and heterotopic ossification. Orthopaedic surgeons have been searching for alternative tissue engineering strategies to enhance bone repair. Our plan is to develop regional gene therapy using transduced bone marrow cells as one aspect of a comprehensive tissue engineering strategy to enhance bone repair. It has been demonstrated in animal models that gene therapy with BMP producing bone marrow cells created via lentiviral gene transfer has the potential to treat either medium or large bone defects or when the biological environment of the host is severely compromised. In this proposal we plan to test our hypothesis that human bone marrow cells transduced with a lentiviral vector to overexpress BMP-2 have the potential to enhance bone repair in humans. Human bone marrow cells will be harvested from the intramedullary canals of patients undergoing total hip arthroplasty. The cells will be transduced with a lentiviral vector (LV-TSTA-iC9/BMP-2) that contains the cDNA for BMP-2 and an inducible suicide gene (iCaspase 9) and then implanted in a critical sized femoral defect model in nude rats. We propose the following aims to accomplish the goal including: 1) compare the efficacy of regional gene therapy after bone repair with freshly isolated or cultured expanded human bone marrow cells; 2) establish a ?cellular dose? of transduced cells that can be scaled up for use in humans; and 3) determine the local and systemic biodistribution of BMP transduced human cells and assess for organ toxicity, vector genotoxicity and heterotopic ossification. The data obtained from this proposal will provide critical information with respect to adapting this regional gene therapy strategy as a treatment regimen in humans.

Public Health Relevance

The ultimate goal of this project is to develop regional gene therapy for the management of difficult bone repair scenarios for which there is no consistently satisfactory solution. These clinical problems include: fractures with extensive bone loss, non-healing fractures, revision total joint replacement and failed spinal fusion. The genetic manipulation of bone marrow cells to overexpress a protein that stimulates progenitor cells to produce bone has significant clinical potential.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
3R01AR057076-08S1
Application #
9906099
Study Section
Program Officer
Wang, Fei
Project Start
2019-08-15
Project End
2022-03-31
Budget Start
2019-08-15
Budget End
2020-03-31
Support Year
8
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Southern California
Department
Orthopedics
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Bougioukli, Sofia; Jain, Ashish; Sugiyama, Osamu et al. (2016) Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect. Bone 84:93-103
Pensak, M; Hong, S; Dukas, A et al. (2015) The role of transduced bone marrow cells overexpressing BMP-2 in healing critical-sized defects in a mouse femur. Gene Ther 22:467-75
Alaee, Farhang; Bartholomae, Cynthia; Sugiyama, Osamu et al. (2015) Biodistribution of LV-TSTA transduced rat bone marrow cells used for ""ex-vivo"" regional gene therapy for bone repair. Curr Gene Ther 15:481-91
Alaee, F; Sugiyama, O; Virk, M S et al. (2014) Suicide gene approach using a dual-expression lentiviral vector to enhance the safety of ex vivo gene therapy for bone repair. Gene Ther 21:139-47
Virk, Mandeep S; Sugiyama, Osamu; Park, Sang H et al. (2011) ""Same day"" ex-vivo regional gene therapy: a novel strategy to enhance bone repair. Mol Ther 19:960-8